JGJenna Ghazal

Jenna Ghazal

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jenna Ghazal has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Mechanistic Interplay Between Multiple Myeloma and Severe SARS-CoV-2 Infection: Therapeutic Promise of Mesenchymal Stem Cell-Derived Extracellular Vesicles

    by Yan Leyfman, Niharika Ikkurthy, Taha Kassim Dohadwala, Helena Sanchez Coloma, Jenna Ghazal, Muskan Joshi, Viviana Cortiana, Diksha Sanjana Pasnoor, Gayathri P. Menon, Noam Levi, et al.

    Patients with multiple myeloma (MM) exhibit profound immune dysregulation, predisposing them to severe outcomes following SARS-CoV-2 infection. Current evidence highlights shared immunopathological mechanisms linking MM and COVID-19, with particular emphasis on the interleukin-6 (IL-6) axis as a shared amplifier of inflammation rather than the sole driver of disease. MM is characterized by a baseline pro-inflammatory milieu, in part mediated by IL-6, which is further amplified during SARS-CoV-2 infection, resulting in cytokine escalation, complement activation, coagulopathy, and multi-organ injury. This amplification operates within a broader, redundant network that also includes T-cell exhaustion, NK-cell dysfunction, checkpoint signaling, complement and endothelial injury, and treatment-induced immune defects. This overlap provides a mechanistic basis for the disproportionately high morbidity and mortality observed in this population. Even with advancements in vaccination, antiviral therapy, and clinical practice, patients with MM who exhibit impaired vaccine responses, active disease, or treatment-related immune dysfunction continue to experience considerable vulnerability to COVID-19. In addition, MM patients demonstrate suboptimal vaccine-induced immune responses, contributing to persistent vulnerability to severe and breakthrough infections. Modern MM therapies, including anti-CD38 antibodies, BCMA-directed agents, and bispecific T-cell redirecting antibodies, further reshape antiviral immunity by reducing NK cells, inducing plasma cell aplasia, causing hypogammaglobulinemia, and impairing T-cell function. Emerging treatment approaches targeting this shared pathway have been explored, with a focus on mesenchymal stem cell (MSC)-derived extracellular vesicles (EVs). EVs exhibit multimodal properties, including suppression of pro-inflammatory cytokines, restoration of immune homeostasis, inhibition of viral entry, and promotion of tissue repair and regeneration. Early clinical experience in severe COVID-19 populations suggests a favorable short-term safety profile; reported efficacy, however, derives from small, largely uncontrolled or early-phase studies, and the single randomized trial reporting a mortality benefit did so only in an exploratory post hoc subgroup, with its pre-specified primary endpoint not met. Overall, EVs constitute a biologically plausible but as yet unproven adjunctive strategy that warrants further investigation. Critically, no MM patient has ever been enrolled in an EV trial; current rationale for EV use in MM is therefore extrapolated entirely from non-MM populations, and no MM-specific data exist. Difficulties such as EV heterogeneity, manufacturing variability, uncertain pharmacokinetics, limited targeting efficiency, and potential prothrombotic effects must be resolved before their application in MM-specific clinical settings.

  • Empowering Global Hematology-Oncology Education: Assessing the Impact of a Virtual Platform in Combating Educational Inequity

    by Yan Leyfman, Viviana Cortiana, Maduri Balasubramanian, Gayathri Pramil Menon, Muskan Joshi, Alexandra Van de Kieft, Harshal Chorya, Jenna Ghazal, Helena S. Coloma, Ghena Khasawneh, et al.

    PURPOSE: Social media informs 77% of patients with cancer, yet one third of posts contain misinformation. MedNews Week (MNW) is a volunteer virtual platform that delivers expert hematology-oncology content while intentionally pursuing gender balance. METHODS: We analyzed program metrics (January 2022-June 2023) for 36 biweekly keynotes by oncology leaders (mean H-index 50.1). Aggregated audience demographics and engagement data were exported from X (Twitter), LinkedIn, YouTube, and Clubhouse. Unique reach, geographic distribution, and growth were calculated after deduplicating cross-platform IDs. Attendance and engagement were compared by speaker gender with χ 2 tests and linear regression. RESULTS: MNW reached 743,991 unique viewers across 95 countries, including 23 low- and middle-income nations, and rose 10.5-fold in attendance over 18 months. Speakers achieved gender parity (18 women, 18 men); female-led sessions drew similar live attendance and video views ( P = .41). MNW ranks in the top 0.07 percentile for health care influence on X. Participants included clinicians (40%), patients/advocates (22%), students (18%), and nonmedical stakeholders (20%). CONCLUSION: A no-cost, volunteer, gender-balanced platform can rapidly scale credible oncology education worldwide, counter misinformation, and engage under-resourced audiences. Sustained partnerships and outcome assessments are warranted.